Additionally, there is some evidence that FGF19 may have regenerative roles within the liver.34 Recent evidence suggests that the FGF19 feedback mechanism is still intact in PBC patients and FGF19 analogues are currently being studied as potential therapeutic agents.36, 43 The FGF19 analogue, NGM282, is currently in phase II clinical trials (NCT02026401). This evidence concerns the gene FGF19 and primary biliary cholangitis.